An update on Vorasidenib

13 January 2026 | Blog, Campaigning and research, News, Treatments

We know that many people in our community are eagerly anticipating NICE’s decision on NHS funding for Vorasidenib. Yesterday, 12 January, it was announced that the appraisal for the drug has been paused, at the request of the drug’s manufacturer, and further guidance is now expected on 29 April 2026.

What does this mean for patients?

Whilst this delay is understandably frustrating, this could be positive news for future availability of Vorasedenib. The appraisal has been paused because, from April, the Government is changing the threshold for whether a drug provides sufficient health benefit to justify its cost. This cost-effectiveness threshold is being increased, meaning that NICE will be able to approve more drugs that previously were considered too expensive. So, the consideration of Vorasedenib has been delayed until April for it to be reviewed under the new threshold rules, and this could improve its chances of approval. If NICE recommends Vorasidenib in April, the NHS then has up to three months to make it available to all eligible patients.

We will share any further update on this as soon as possible, as well as the assessment by the Scottish Medicines Consortium for Vorasidenib’s use in Scotland.

Our Head of Support, Lucy Wilkinson, shared her continued hope for Vorasidenib being approved, saying,

“We know that many people affected by a low grade glioma have been awaiting the decision on Vorasidenib, so we recognise how frustrating this delay may feel, and Brain Tumour Support is here for anyone who needs space to talk or seek support at this time. We want to again thank everyone who shared personal stories with us and other organisations, or directly, as evidence to NICE. This has been a powerful community voice and we remain committed and hopeful that there will be a positive outcome.”

Read about Vorasidenib from a patient’s perspective here.